These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 31880641)

  • 1. Effects of Long-Term Exercise on Liver Cyst in Polycystic Liver Disease Model Rats.
    Sato Y; Qiu J; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2020 Jun; 52(6):1272-1279. PubMed ID: 31880641
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
    Sato Y; Qiu J; Hirose T; Miura T; Sato Y; Kohzuki M; Ito O
    Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G464-G473. PubMed ID: 33439105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan ameliorates fibrocystic liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kugita M; Sasaki M; Horie S; Nakanishi K; Abe T; Aukema HM; Yamaguchi T; Nagao S
    PLoS One; 2013; 8(12):e81480. PubMed ID: 24324698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic Exercise Protects against the Progression of Renal Cyst Growth and Dysfunction in Rats with Polycystic Kidney Disease.
    Qiu J; Sato Y; Xu L; Miura T; Kohzuki M; Ito O
    Med Sci Sports Exerc; 2021 Dec; 53(12):2485-2494. PubMed ID: 34310502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
    Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
    Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Everolimus halts hepatic cystogenesis in a rodent model of polycystic-liver-disease.
    Temmerman F; Chen F; Libbrecht L; Vander Elst I; Windmolders P; Feng Y; Ni Y; De Smedt H; Nevens F; van Pelt J
    World J Gastroenterol; 2017 Aug; 23(30):5499-5507. PubMed ID: 28852309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate.
    Masyuk TV; Masyuk AI; Torres VE; Harris PC; Larusso NF
    Gastroenterology; 2007 Mar; 132(3):1104-16. PubMed ID: 17383431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPAR-gamma agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease.
    Yoshihara D; Kurahashi H; Morita M; Kugita M; Hiki Y; Aukema HM; Yamaguchi T; Calvet JP; Wallace DP; Nagao S
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F465-74. PubMed ID: 21147840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cholangiocyte autophagy contributes to hepatic cystogenesis in polycystic liver disease and represents a potential therapeutic target.
    Masyuk AI; Masyuk TV; Lorenzo Pisarello MJ; Ding JF; Loarca L; Huang BQ; LaRusso NF
    Hepatology; 2018 Mar; 67(3):1088-1108. PubMed ID: 29023824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of Mast Cell Degranulation With Cromolyn Sodium Exhibits Organ-Specific Effects in Polycystic Kidney (PCK) Rats.
    Jiang L; Fang P; Septer S; Apte U; Pritchard MT
    Int J Toxicol; 2018; 37(4):308-326. PubMed ID: 29862868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. B-type natriuretic peptide overexpression ameliorates hepatorenal fibrocystic disease in a rat model of polycystic kidney disease.
    Holditch SJ; Schreiber CA; Harris PC; LaRusso NF; Ramirez-Alvarado M; Cataliotti A; Torres VE; Ikeda Y
    Kidney Int; 2017 Sep; 92(3):657-668. PubMed ID: 28416225
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of a Histone Deacetylase 6 Inhibitor and a Somatostatin Receptor Agonist Synergistically Reduces Hepatorenal Cystogenesis in an Animal Model of Polycystic Liver Disease.
    Lorenzo Pisarello M; Masyuk TV; Gradilone SA; Masyuk AI; Ding JF; Lee PY; LaRusso NF
    Am J Pathol; 2018 Apr; 188(4):981-994. PubMed ID: 29366679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.
    Sato Y; Harada K; Furubo S; Kizawa K; Sanzen T; Yasoshima M; Ozaki S; Isse K; Sasaki M; Nakanuma Y
    Am J Pathol; 2006 Oct; 169(4):1238-50. PubMed ID: 17003482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adenylyl cyclase 5 links changes in calcium homeostasis to cAMP-dependent cyst growth in polycystic liver disease.
    Spirli C; Mariotti V; Villani A; Fabris L; Fiorotto R; Strazzabosco M
    J Hepatol; 2017 Mar; 66(3):571-580. PubMed ID: 27826057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bile Acids in Polycystic Liver Diseases: Triggers of Disease Progression and Potential Solution for Treatment.
    Perugorria MJ; Labiano I; Esparza-Baquer A; Marzioni M; Marin JJ; Bujanda L; Banales JM
    Dig Dis; 2017; 35(3):275-281. PubMed ID: 28249268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models.
    Lee-Law PY; Olaizola P; Caballero-Camino FJ; Izquierdo-Sanchez L; Rodrigues PM; Santos-Laso A; Azkargorta M; Elortza F; Martinez-Chantar ML; Perugorria MJ; Aspichueta P; Marzioni M; LaRusso NF; Bujanda L; Drenth JPH; Banales JM
    J Hepatol; 2021 Feb; 74(2):394-406. PubMed ID: 32950589
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic cystogenesis is associated with abnormal expression and location of ion transporters and water channels in an animal model of autosomal recessive polycystic kidney disease.
    Banales JM; Masyuk TV; Bogert PS; Huang BQ; Gradilone SA; Lee SO; Stroope AJ; Masyuk AI; Medina JF; LaRusso NF
    Am J Pathol; 2008 Dec; 173(6):1637-46. PubMed ID: 18988797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epithelial-to-mesenchymal transition in cyst lining epithelial cells in an orthologous PCK rat model of autosomal-recessive polycystic kidney disease.
    Togawa H; Nakanishi K; Mukaiyama H; Hama T; Shima Y; Sako M; Miyajima M; Nozu K; Nishii K; Nagao S; Takahashi H; Iijima K; Yoshikawa N
    Am J Physiol Renal Physiol; 2011 Feb; 300(2):F511-20. PubMed ID: 21084407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased water intake decreases progression of polycystic kidney disease in the PCK rat.
    Nagao S; Nishii K; Katsuyama M; Kurahashi H; Marunouchi T; Takahashi H; Wallace DP
    J Am Soc Nephrol; 2006 Aug; 17(8):2220-7. PubMed ID: 16807403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.